Aristotelis Nastos

About

Aristotelis joined Biomed as Managing Partner in 2023 and has a long-standing career in the European venture capital industry. During this time, he has been involved in numerous financing rounds as well as several trade sales. Before joining Biomed, he worked at NRW.BANK in Düsseldorf as Head of Life Sciences, where he was responsible for a portfolio of a total of 35 companies. He also served on the boards of several of these companies, including Emergence (sold to Lilly in 2023), CEVEC (sold to Cytiva in 2022), Scienion (sold to Cellink/BICO in 2020), Rigontec (sold to MSD in 2017), and Direvo (sold to Bayer in 2008). He began his venture capital career at Peppermint in Berlin and later also served as a Partner at Creathor Ventures in Bad Homburg. Telis holds a degree in Biology and completed his PhD at the Institute for Cell Biology at the University Hospital in Essen. He subsequently received a Wellcome International Research Fellowship and moved to King’s College London for a postd

Source (opens in a new tab)